Hospital News

The Clinic by Cleveland Clinic Launches New Multidisciplinary Virtual Second Opinion Program for Brain and Prostate Cancer

CLEVELAND--(BUSINESS WIRE)--The Clinic by Cleveland Clinic™, a transformative joint venture between Cleveland Clinic and Amwell® (NYSE: AMWL) that aligns world-class clinical expertise with the...

Admin - May 18, 2021

Hospital News

Vizient Announces New Member Agreement with Antelope Valley Hospital

IRVING, Texas--(BUSINESS WIRE)--Vizient, Inc. today announced a new agreement with Antelope Valley Hospital, based in Lancaster, California. In addition to access Vizient’s group purchasing...

Admin - April 26, 2021

Hospital News

Children’s Hospital Los Angeles Joins 10 Other Leading Children’s Hospitals and Phlow Corp. to form an Unprecedented Coalition to Deliver Essential Medicines to Address...

LOS ANGELES--(BUSINESS WIRE)--Children's Hospital Los Angeles (CHLA) today joins in announcing the launch of a groundbreaking Children's Hospital Coalition: Powered by Phlow™ (CHC). This...

Admin - March 18, 2021

Hospital News

Applied DNA and Evvivax Initiate Phase I of Clinical Trial to Evaluate LinearDNA™ COVID-19 Vaccine Candidate for Feline Veterinary Market

STONY BROOK, N.Y. & ROME--(BUSINESS WIRE)--Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, and its...

Admin - March 2, 2021

Hospital News

Altasciences Performs Phase I Studies for FDA Approval of Vibegron

LAVAL, Quebec--(BUSINESS WIRE)--Altasciences is pleased to have contributed to the recent FDA approval of Vibegron, by performing three early phase clinical trials. Vibegron is...

Admin - February 23, 2021

Hospital News

Abzena Selected by Immunome to Develop and Manufacture Antibody Cocktail for Immunome’s COVID-19 Antibody Based Treatment

EXTON, Pa. & SAN DIEGO--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company utilizing a proprietary human memory B cell platform to discover and develop...

Admin - February 3, 2021

12 3...15 Page 1 of 15

Immune-Onc Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating IO-108, a Novel Antagonist Antibody Targeting LILRB2 (ILT4), in Patients With Advanced...

Industry News October 14, 2021

Former Goldman Sachs VP Jim Johnston Joins Greyledge Technologies as Chief of Corporate Development

Look Who’s On the Move! October 14, 2021

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Bevacizumab, as Treatment for Patients With Persistent, Recurrent or Metastatic Cervical Cancer Whose Tumors...

Industry News October 14, 2021

New 4-Year Data Show Genentech’s Enspryng (satralizumab-mwge) Significantly Reduces Debilitating Relapses in People With Neuromyelitis Optica Spectrum Disorder

Industry News October 14, 2021

Kyowa Kirin International: New Real World Evidence Underlines Benefits of POTELIGEO®▼ (mogamulizumab) Treatment for Cutaneous T-cell Lymphoma (CTCL) Patients

Industry News October 14, 2021

New Data Reinforce the Relationship Between B-Cell Depletion and Improved Outcomes in People Receiving UPLIZNA® (inebilizumab-cdon) for Neuromyelitis Optica Spectrum Disorder (NMOSD)

Industry News October 13, 2021

Richard Kho, PhD, and Murali Gopal, MD, Join Iterative Scopes in Senior Leadership Roles

Look Who’s On the Move! October 13, 2021

ImmunityBio Completes Enrollment in Phase 2 Study of Nant Cancer Vaccine for 3rd Line or Greater Metastatic Pancreatic Cancer Patients—90% of Patients Have Exceeded...

Industry News October 13, 2021

Otsuka and Lundbeck Announce FDA Acceptance of Supplemental New Drug Application; Receive Priority Review for Treatment of Schizophrenia in Adolescents

Regulatory Affairs October 13, 2021

Hospital News

Recent Articles

Immune-Onc Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating IO-108, a Novel Antagonist Antibody Targeting LILRB2 (ILT4), in Patients With Advanced...

Former Goldman Sachs VP Jim Johnston Joins Greyledge Technologies as Chief of Corporate Development

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Bevacizumab, as Treatment for Patients With Persistent, Recurrent or Metastatic Cervical Cancer Whose Tumors...

New 4-Year Data Show Genentech’s Enspryng (satralizumab-mwge) Significantly Reduces Debilitating Relapses in People With Neuromyelitis Optica Spectrum Disorder

Kyowa Kirin International: New Real World Evidence Underlines Benefits of POTELIGEO®▼ (mogamulizumab) Treatment for Cutaneous T-cell Lymphoma (CTCL) Patients

Vedanta Biosciences Appoints Simona Levi as Chief Legal Officer and Corporate Secretary

Kojin Therapeutics Announces Luba Greenwood as Chief Executive Officer

OnKure Therapeutics Appoints Jennifer R. Diamond, M.D., as Chief Medical Officer

PureTech Founded Entity Vedanta Biosciences Appoints Simona Levi as Chief Legal Officer and Corporate Secretary

Immusoft and Takeda Collaborate to Discover and Develop Cell Therapies for Rare Neurometabolic Disorders

Canada’s Bio-Economy Facing Severe Labour Shortage

New Data Reinforce the Relationship Between B-Cell Depletion and Improved Outcomes in People Receiving UPLIZNA® (inebilizumab-cdon) for Neuromyelitis Optica Spectrum Disorder (NMOSD)

Richard Kho, PhD, and Murali Gopal, MD, Join Iterative Scopes in Senior Leadership Roles

ImmunityBio Completes Enrollment in Phase 2 Study of Nant Cancer Vaccine for 3rd Line or Greater Metastatic Pancreatic Cancer Patients—90% of Patients Have Exceeded...

Otsuka and Lundbeck Announce FDA Acceptance of Supplemental New Drug Application; Receive Priority Review for Treatment of Schizophrenia in Adolescents